Abstract
A golden age of antiepileptic drug development has yielded over a dozen useful new compounds, but the nature of clinical trials has made translation to practical use in the clinic difficult. Most clinical trials are designed for regulatory purposes and fail to answer critical clinical questions. These questions include: which drug is best as initial therapy, which drugswork as monotherapy, what are good drug combinations, what is the best starting dose and titration schedule, what is a reasonable target dose, what is the shape of the dose-response curve and does it vary significantly between patients, what is the true incidence of side effects, and what is the long-term efficacy of the drug? Most of these questions could be answered by changing trial designs, but many changes would entail additional time and money. There are encouraging signs that trials with procedures more directly applicable to the clinic are becoming common. These include direct comparative trials, longer trials with emphasis on seizure freedom, and trials with more flexible dosing schedules. In the past, funding of longer and more naturalistic trials has fallen to government agencies, but commercial funding has been obtained for several recent studies. Better quality control, innovative endpoints, structured searching for side effects, and standardisation of data collection are also promising topics for development.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Anderson M, Choonara I. A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period. Arch Dis Child 2010; 95: 731–738.
Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebocontrolled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597–1607.
Baulac M, Leon T, O’Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial-onset seizures. Epilepsy Res 2010; 91: 10–19.
Ben-Menachem E, Sander JW, Privitera M, Gilliam F. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav 2010; 18: 24–30.
Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010; 51: 7–26.
Brodie MA, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Research 1997; 26: 423–432.
Chadwick D, Shukralla A, Marson T. Comparing drug treatments in epilepsy. Ther Adv Neurol Disord 2009; 2: 181–187.
Cowling BJ, Shaw JE, Hutton JL, Marson AG. New statistical method for analyzing time to first seizure: example using data comparing carbamazepine and valproate monotherapy. Epilepsia 2007; 48: 1173–1178.
Faught E, Ayala R, Montouris GG, Leppik IE, Zonisamide 922 Study Group IE. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–1779.
French JA. Proof of efficacy trials: endpoints. Epilepsy Research 2001; 45: 53–56.
French JA, Faught E. Rational polytherapy. Epilepsia 2009; 50: 63–68.
Garofalo E. Obtaining pediatric indications for new antiepileptic drugs: how and when. Epilepsy Res 2006; 68: 38–42.
Gilliam F. What we don’t learn from clinical trials in epilepsy. Epilepsia 2003; 44: 51–54.
Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004; 62: 23–27.
Gilliam FG, Barry JJ, Herman BP, Meador KJ, Vahle V, Kanner AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 2006; 5: 399–405.
Glauser T, Ben-Menachem E, Bourgeois B, et al. International League Against Epilepsy treatment guidelines: evidencebased analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094–1120.
Glauser T, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362: 790–799.
Hopkins AC, Davies P, Dobson C. Mathematical models of patterns of seizures. Their use in the evaluation of drugs. Arch Neurol 1985; 42: 463–467.
Kwan P, Brodie MJ. Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy. Neurology 2003; 60(Suppl. 4): S2–S12.
Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011; 52: 657–678.
Luszczki JJ, Filip D, Czuczwar SJ. Additive interactions of pregabalin with lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis for non-parallel dose-response relationship curves. Epilepsy Res 2010; 91: 166–175.
Marson AG, Williamson P. Interpreting regulatory trials in epilepsy. Current Opinion in Neurology 2009; 22: 167–173.
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007a; 369: 1000–1015.
Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007b; 369: 1016–1026.
Meador KJ, Pennell PB, Harden CL, et al. Pregnancy registries in epilepsy. Aconsensus statement on health outcomes. Neurology 2008; 71: 1109–1117.
Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. J Clin Neurol 2008; 4: 99–106.
Pellock JM, Faught E, Leppik IO, Shinnar S, Zupanc ML. Felbamate: consensus of current experience. Epilepsy Research 2006; 71: 81–101.
Perucca E. Designing clinical trials to assess antiepileptic drugs as monotherapy: difficulties and solutions. CNS Drugs 2008; 22: 917–938.
Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999; 33: 247–262.
Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009; 72: 1223–9122.
Physician’s Desk Reference. Keppra XR labeling recommendations; Lamictal labeling recommendations, PDR Consortium, 2011a, 2011b.
Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107: 165–175.
Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized doubleblind clinical trial. Epilepsia 2010; 51: 1970–1975.
Rheims S, Percucca E, Cucherat M, Ryvlin P. Factors determing response to antiepileptic drugs in randomized controlled trials. A systematic review and metanalysis. Epilepsia 2011; 52: 219–233.
Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy. Arandomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64:1868–1873.
Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebocontrolled randomised trials. Lancet Neurology 2011; 10: 961–968.
Sake JK, Hebert D, Isojarvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010; 24: 1055–1068.
Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32: 157–163.
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–1097.
Talati R, Scholle JM, Phung OJ, et al. Effectiveness and safety of antiepileptic medications in patients with epilepsy. Comparative Effectiveness Review No. 40. AHRQ Publication No. 11, 2011; (12)-EHC082-EF. Rockville (MD): Agency for Healthcare Research and Quality. www.effectivehealthcare.ahrq.gov/reports/final.cfm (accessed Jan 1, 2012).
Weijenberg A, Offringa M, Brouwer OF, Callenbach PM. RCTs with new antiepileptic drugs in children: a systematic review of monotherapy studies and their methodology. Epilepsy Res 2010; 91: 1–9.
World Health Organization. WHO defined daily doses of antiepileptic drugs. 2010. Retrieved 10 October 2011, from www.WHOCC.no/atc_ddd_index/?code=NO3A.
Author information
Authors and Affiliations
Corresponding author
Additional information
Updated following presentation and discussion at the 2011 Progress in Epileptic Disorders Workshop on “Antiepileptic Drug Trials: will the future challenge the past” held at the Chaeauform’ La Maison des Contes, Dareizé, 69490, France. The workshop was partly supported by an educational grant from UCB. The program was under the exclusive responsibility of a Scientific Committee composed by Prs. Philippe Ryvlin (France), Emilio Perucca (Italy), Jackie French (USA), Steve White (USA), Graeme Sills (UK) and Alexis Arzimanoglou (France).
About this article
Cite this article
Faught, E. Antiepileptic drug trials: the view from the clinic. Epileptic Disord. 14, 114–123 (2012). https://doi.org/10.1684/epd.2012.0510
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0510